Ocugen (NASDAQ:OCGN) Posts Quarterly Earnings Results

Ocugen (NASDAQ:OCGN) posted its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02), FiscalAI reports. The firm had revenue of $1.49 million for the quarter, compared to analyst estimates of $0.89 million.

Here are the key takeaways from Ocugen’s conference call:

• OCU410 received FDA clearance to begin its Phase III ARMADA-3 trial in geographic atrophy, along with RMAT designation. The approximately 237-patient global study is expected to start by September 2026, supported by Phase II data showing a 31% reduction in lesion growth at the optimal dose.
• Ocugen expects several major clinical catalysts, including an interim decision for OCU410ST in Stargardt disease in the third quarter of 2026 and top-line data for OCU400 and OCU410ST in the first half of 2027. Management continues to target three BLA submissions by 2028.
• Enrollment is complete in the 140-patient Phase III liMeliGhT trial for OCU400 in broad retinitis pigmentosa, with top-line data expected in the first quarter of 2027. The company also completed manufacturing qualification batches intended to support potential BLA filings and commercial supply.
• Ocugen closed a $130 million convertible notes financing, reporting $100.4 million in cash, cash equivalents, and restricted cash at June 30, which management says extends its runway into 2028. It also signed a binding term sheet granting Roots Pharmaceutical and Al-Dhow International exclusive OCU400 rights in the Middle East and North Africa.
• Operating expenses increased to $17.9 million in the quarter from $15.2 million a year earlier, while quarterly net loss widened to $0.07 per share from $0.05. Management is evaluating additional financing, warrant exercises, business-development transactions, and a potential share authorization increase, creating possible future dilution.

Ocugen Price Performance

Ocugen stock opened at $1.27 on Friday. The firm has a market capitalization of $430.67 million, a PE ratio of -4.88 and a beta of 2.21. Ocugen has a 52 week low of $0.96 and a 52 week high of $2.73. The firm’s 50-day simple moving average is $1.34 and its 200 day simple moving average is $1.56. The company has a quick ratio of 1.86, a current ratio of 1.86 and a debt-to-equity ratio of 4.17.

Insiders Place Their Bets

In other Ocugen news, CFO Treerita Essali Johnson-Greene bought 21,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was bought at an average price of $1.23 per share, for a total transaction of $25,830.00. Following the completion of the transaction, the chief financial officer owned 521,000 shares in the company, valued at approximately $640,830. The trade was a 4.20% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.95% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of OCGN. Creative Planning acquired a new stake in Ocugen during the 2nd quarter valued at $57,000. XTX Topco Ltd purchased a new position in Ocugen during the second quarter worth $203,000. Jump Financial LLC acquired a new position in shares of Ocugen in the second quarter worth $57,000. Qube Research & Technologies Ltd acquired a new position in shares of Ocugen in the second quarter worth $188,000. Finally, NewEdge Advisors LLC lifted its position in shares of Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock valued at $36,000 after acquiring an additional 24,460 shares in the last quarter. 10.27% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on OCGN. Weiss Ratings lowered shares of Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Wall Street Zen lowered Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Canaccord Genuity Group lowered their price target on Ocugen from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ocugen has an average rating of “Moderate Buy” and a consensus price target of $9.50.

Trending Headlines about Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: The FDA cleared Ocugen to begin the Phase 3 OCU410 trial for geographic atrophy associated with dry age-related macular degeneration. The program also received Regenerative Medicine Advanced Therapy designation, potentially enabling priority review and accelerated approval. Ocugen targets three BLAs by 2028
• Positive Sentiment: Ocugen completed a $130 million convertible-notes financing, using roughly $32.7 million to retire higher-cost Avenue Capital debt and extending its expected cash runway into 2028. Cash and restricted cash totaled $100.4 million at June 30. Ocugen second-quarter business update
• Positive Sentiment: The company reported progress across its late-stage pipeline: OCU410 Phase 3 is expected to start this quarter, OCU400 enrollment is complete with topline data expected in the first quarter of 2027, and OCU410ST data are anticipated in the second quarter of 2027. Ocugen Q2 2026 earnings call highlights
• Positive Sentiment: A proposed OCU400 licensing arrangement for the Middle East and North Africa could provide up to $255 million in sales milestones, royalties of 22% on net sales, and an upfront payment. Ocugen reports Q2 results and advances OCU410
• Neutral Sentiment: Second-quarter revenue was $1.49 million, above the $0.89 million analyst estimate, but remains small relative to the company’s development costs. Ocugen reports Q2 loss and beats revenue estimates
• Negative Sentiment: Ocugen’s quarterly loss widened to $0.07 per share from $0.05 a year earlier, missing the $0.05 consensus estimate. Research and development spending rose to $10.7 million, pushing total operating expenses to $17.9 million. Ocugen Q2 earnings miss as R&D costs rise
• Negative Sentiment: The financing improves liquidity but adds convertible debt and potential future share dilution. Ocugen also reported a $24.9 million net loss for the quarter and an accumulated deficit of $452.1 million, underscoring its ongoing dependence on capital markets.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.